A 12-Week Randomized, Double-blind, Parallel-group, Placebo-controlled Trial With and Open-label, 12-week Extension, Multicenter to Evaluation of the Efficacy of Escitalopram for the Treatment of Depression in Alzheimer's Disease
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Escitalopram (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- 13 Aug 2014 Biomarkers information updated
- 06 Dec 2013 Planned End Date changed from 1 Jun 2014 to 1 Aug 2014 as reported by ClinicalTrials.gov.
- 07 May 2013 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.